- Home
- CHCT vs DCTH Comparison
CHCT vs DCTH Comparison
Compare CHCT & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHCT
- DCTH
- Stock Information
- Founded
- CHCT 2014
- DCTH 1988
- Country
- CHCT United States
- DCTH United States
- Employees
- CHCT N/A
- DCTH N/A
- Industry
- CHCT Real Estate Investment Trusts
- DCTH Medical/Dental Instruments
- Sector
- CHCT Real Estate
- DCTH Health Care
- Exchange
- CHCT Nasdaq
- DCTH Nasdaq
- Market Cap
- CHCT 425.5M
- DCTH 388.3M
- IPO Year
- CHCT 2015
- DCTH N/A
- Fundamental
- Price
- CHCT $14.17
- DCTH $10.76
- Analyst Decision
- CHCT Buy
- DCTH Strong Buy
- Analyst Count
- CHCT 2
- DCTH 4
- Target Price
- CHCT $18.00
- DCTH $24.50
- AVG Volume (30 Days)
- CHCT 201.8K
- DCTH 689.4K
- Earning Date
- CHCT 10-28-2025
- DCTH 11-07-2025
- Dividend Yield
- CHCT 13.35%
- DCTH N/A
- EPS Growth
- CHCT N/A
- DCTH N/A
- EPS
- CHCT N/A
- DCTH 0.06
- Revenue
- CHCT $118,100,000.00
- DCTH $70,240,000.00
- Revenue This Year
- CHCT $6.73
- DCTH $159.22
- Revenue Next Year
- CHCT $6.07
- DCTH $42.78
- P/E Ratio
- CHCT N/A
- DCTH $192.85
- Revenue Growth
- CHCT 2.96
- DCTH 491.35
- 52 Week Low
- CHCT $14.16
- DCTH $8.08
- 52 Week High
- CHCT $20.87
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- CHCT 31.03
- DCTH 44.88
- Support Level
- CHCT $14.97
- DCTH $10.43
- Resistance Level
- CHCT $15.48
- DCTH $11.28
- Average True Range (ATR)
- CHCT 0.31
- DCTH 0.45
- MACD
- CHCT -0.08
- DCTH -0.03
- Stochastic Oscillator
- CHCT 3.18
- DCTH 19.34
About CHCT Community Healthcare Trust Incorporated
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers in non-urban markets. The company derives majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.